SAGE Therapeutics to Participate in the 2014 Leerink Partners Rare Disease Roundtable

CAMBRIDGE, Mass., Sept. 25, 2014 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced management will participate in the 2014 Leerink Partners Rare Disease Roundtable on Wednesday, October 1 at Le Parker Meridian Hotel in New York City. Jeff Jonas, chief executive officer of SAGE, will participate in a fireside chat with Leerink Partners' analyst Joseph P. Schwartz at 10:40 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the "Investors & Media" section of the company's website at A replay of the webcast will be archived on the SAGE website for 60 days following the presentation.

About SAGE Therapeutics

SAGE Therapeutics (Nasdaq:SAGE) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. For more information, please visit

CONTACT: Media Contact: Dan Budwick, Pure Communications 973-271-6085 Investor Contact: Monique Allaire, Pure Communications 781-631-0759

Source:SAGE Therapeutics